34 results about "Beta lactams" patented technology

The present invention relates to a method of simultaneously detecting a plurality of agro-veterinary drug residues in bee products. The extracted liquid trichloroacetic acid or perchloric acid and the extracted liquid acetate, phosphate or borate solution are added into a sample; the pH value is controlled between 4.5 and 9.0; the mixed solution is centrifuged, the filtrate is added into a solid phase extraction column to be extracted, the extraction column is eluted and dried, the column is washed by oxalic acid-methanol solution, the volume of the eluent is defined by the aqueous solution of methanol, the eluent is added into liquid chromatography-tandem mass spectrometry to be analyzed and tested, the acquired chromatographic peak is contrasted with the known standard chromatographic peak of the drug, and according to the retention time and the abundance of the mass spectrum ions, the specific name of the detected drug is determined. The method only requires one pre-treatment of the sample, and thus can simultaneously extract 11 classes and more than 60 kinds of veterinary drug residues, such as sulfonamides, quinolones, macrolides, lincomycins, nitroimidazoles, beta-lactams, tetracyclines, chloromycetins, trinethoprims, chlordimeform, triadimenol and the like, the efficiency of analysis is high, and the detection cost is greatly reduced.

The invention relates generally to novel N-thiolated beta-lactams. More specifically, the invention relates to the use of these novel antibacterial agents in the treatment or inhibition of methicillin-resistant Staphylococcus aureus.

The invention provides a hapten comprising a 6-[D-alpha-aminoacetamido]penicillin derivative crosslinked at the alpha-amino group with a substituted or unsubstituted phenyldicarbaldehyde. In addition, the invention provides an immunogen comprising the aforementioned hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of an intact beta-lactam ring. The invention further provides a method and a kit for detecting, or determining the quantity of, beta-lactam antibiotics, as well as, use of the aforementioned conjugate with the aforementioned antibodies for detecting, or determining the quantity of, beta-lactam antibiotics. The present invention has broad specificity across the main first generation beta-lactams and can be used to test milk and meat and the like for the presence of residual beta-lactam antibiotics.

Disclosed is a method for preparing compound beta lactam sodium salt/sodium benemid for injection, which comprises dissolving 1-10 weight parts of probecid into 1-100 parts of water, charging sodium ion-containing alkaline solution, adjusting pH to 6-11 for reaction into salts, filtering and degerming through microporous filtering film, asepsis drying, or filtering with microporous filtering film and charging 10-100 parts of absolute ethyl alcohol or waterless acetone for evolution of solid body, carrying out asepsis dehydration obtain the end product, mixing sodium salt of beta-lactams with the obtained sodium benemid by the proportion of 10:1-1:10 and dissolving into 1-100 parts of water.

The invention discloses a heterogeneous biocatalyst taking alpha-amino-acid ester hydrolase as basis, a preparation method thereof and application in synthesizing amino beta-lactams. The activity of catalyst synthetase is 2,200 U/g by dry weight, and the content of protein is 0.95 g/g by dry weight; and xanthomonas rubrilineans cell biomass is processed in an organic solvent under a pH gradient through low temperature effect to extract enzyme, and enzyme aggregates are deposited and cross-linked to obtain the hydrolase. The alpha-amino-acid ester hydrolase as a catalyst can be synthesized into amino penicillin and amino cephalosporin drugs through acylating a beta-lactam compound by D-phenylglycine methyl ester derivatives in water or in a mixed medium of water and an organic solvent.

Disclosed herein is a compound comprising a formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

Y is

A is —(CH₂)₆—, cis —CH₂CH═CH—(CH₂)₃—, or —CH₂C≡C—(CH₂)₃—, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is —(CH₂)_m—Ar—(CH₂)_o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH₂ may be substituted with S or O; and

D is aryl or heteroaryl.

Methods of use are also disclosed.

The invention relates to a new pharmaceutical composition, a method of treatment of infection and also a process to prepare the composition. The infectious complications are important causes of morbidity and mortality. Hospital acquired pneumonia (HAP) remains the most severe nosocomial infection in intensive care units. Beta-lactams alone are always considered inadequate when P. aeruginosa and/or methicillin-resistant S. aureus are implicated as pathogens or copathognes. The present invention provides the desired empirical therapy for control of all bacterial infections. The invention provides antibiotic combination products for delivering at least two different antibiotics, through parenteral dosage form comprising protein-synthesis-inhibiting antibiotic which is amikacin or its sulphate salt and non-protein-synthesis-inhibiting antibiotic which is cefepime or its hydrochloride salt. The invention provides a total solution, against multiresistant P. aeruginosa, or Acinetobacter spp. and/or methicillin-resistant S. aureus, and are useful for intramuscular or intravenous administration as antibiotics for hospitalized patients with acute or serious infections. The pharmaceutical compositions described here normally have the least nephrotoxicity and have better efficacy and safety of cefepime plus amikacin combination.

The invention discloses a fluorescent indicator combination, a fluorescence array sensor, preparation methods of the fluorescent indicator combination and the fluorescence array sensor and application. The fluorescent indicator combination comprises a plurality of carbon quantum dot-metal ion complexes formed by full-color fluorescent carbon quantum dots and various metal ions under conditions ofdifferent pH values. The fluorescent array sensor contains a fluorescent indicator; the sensor comprises a plurality of groups of response points; each group of response points comprise three or moreindependent response points respectively corresponding to excitation wavelengths of 360 nm, 450 nm, and 540 nm; and each of the response points comprises at least one carbon quantum dot-metal ion complex. The fluorescent array sensor of the invention can realize qualitative and semi-quantitative detection of four kinds of antibiotics such as tetracyclines, quinolones, beta-lactams and aminoglycosides; and the preparation process of the sensor is simple; the storage time of the sensor is long; the detection sensitivity of the sensor is high; and the sensor can realize simultaneous differentiation and detection of a plurality of antibiotics.

The invention relates to a method for treating infections of bacteria of the Chlamydiaceae family using a β-lactam. The invention also relates to a method for treating diseases caused by an infection of bacteria of the Chlamydiaceae family using a β-lactam.

The present invention relates in general to the use of amphiphilic graft-type copolymers of polyaspartamide for the ophthalmic administration of drugs, such as for example steroidal and non-steroidal anti-inflammatory agents, antimicrobial agents such as aminoglycosides, macrolides, cephalosporin, tetracycline, quinolones, penicillin, beta-lactams, anti-glaucoma agents such as prostaglandins, alpha- and beta-blockers, inhibitors of carbonic anhydrase, cannabinoids, antiviral agents, diagnostic agents, anti-angiogenic agents, antioxidants.

The invention discloses cleavable multiple-drug resistant pseudomonas aeruginosa bacteriophage and application thereof in infection treatment. The invention discloses cleavable pseudomonas aeruginosa bacteriophage multiple-resistant to beta-lactams, aminoglycosides and cephalosporin antibiotics, which is named as PaP No.106, preserved in China Center for Type CultureCollection(CCTCC) (Budapest treaty preservation unit, Wuhan University, Wuhan City, China) in June 1, 2012 and has the preservation number of CCTCC NO:M2012200. On the basis of the purpose of novel anti infective therapy, the separated and purified cleavable multiple-drug resistant pseudomonas aeruginosa bacteriophage is proved to be capable of cleaving into multi strains of pseudomonas aeruginosa multiple-resistant to beta-lactams (including carbapenems), aminoglycosides and cephalosporin antibiotics in vitro and vivo, so that the cleavable multiple-drug resistant pseudomonas aeruginosa bacteriophage is proved to be feasible in treatment of pseudomonas aeruginosa infection, and a new therapeutic approach for clinical drug resistant bacteria infection is provided.

The present invention provides new and effective liposomal fomiulations for the administration of beta-lactams.

The invention discloses a pharmaceutical composition and an application thereof, which belongs to the technical field of a medicine. The pharmaceutical composition comprises fusaric acid or a fusaricacid compound and one of quinolone, beta-lactams and/or tetracycline antibiotic or a plurality of antibiotics with a mass ratio of 1: 500-128:1, and is used for preparing a medicine for treating and preventing diseases due to drug-resistant bacteria. The composition can effectively solve the drug resistance problem of bacteria on a plurality of antibiotics, the components have synergistic interaction effect, the usage of antibiosis drugs in clinical application of the antibiosis drugs is reduced, side effect and the treatment cost generated due to antibiotic can be correspondingly reduced, andthe sensitivity of the antibiosis drugs can be reduced.